Corbus Pharmaceuticals (NASDAQ:CRBP) Trading Down 5%

Share on StockTwits

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)’s share price was down 5% on Thursday . The stock traded as low as $5.90 and last traded at $5.68, approximately 58,278 shares were traded during mid-day trading. A decline of 94% from the average daily volume of 905,509 shares. The stock had previously closed at $5.98.

Several analysts recently weighed in on CRBP shares. BidaskClub lowered Corbus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 29th. Zacks Investment Research raised Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 28th. HC Wainwright reaffirmed a “buy” rating and set a $24.00 target price on shares of Corbus Pharmaceuticals in a report on Monday, December 23rd. Finally, ValuEngine raised Corbus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $23.71.

The company has a fifty day moving average price of $6.32 and a 200 day moving average price of $5.46. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.27.

Hedge funds have recently modified their holdings of the stock. State Street Corp grew its holdings in Corbus Pharmaceuticals by 5.6% in the 3rd quarter. State Street Corp now owns 1,099,507 shares of the biopharmaceutical company’s stock worth $5,355,000 after buying an additional 58,547 shares in the last quarter. Squarepoint Ops LLC bought a new position in Corbus Pharmaceuticals in the 3rd quarter worth approximately $127,000. Aries Wealth Management grew its holdings in Corbus Pharmaceuticals by 9.8% in the 4th quarter. Aries Wealth Management now owns 27,900 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 2,500 shares in the last quarter. Parametric Portfolio Associates LLC bought a new position in Corbus Pharmaceuticals in the 2nd quarter worth approximately $123,000. Finally, Russell Investments Group Ltd. bought a new position in Corbus Pharmaceuticals in the 3rd quarter worth approximately $1,062,000. 49.83% of the stock is owned by institutional investors and hedge funds.

About Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis.

Read More: Do You Need a Fiduciary?

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cetera Advisors LLC Has $483,000 Stake in Office Properties Income Trust
Cetera Advisors LLC Has $483,000 Stake in Office Properties Income Trust
Cetera Advisors LLC Trims Holdings in Intercontinental Exchange Inc
Cetera Advisors LLC Trims Holdings in Intercontinental Exchange Inc
Unilever NV  Shares Bought by Cetera Advisors LLC
Unilever NV Shares Bought by Cetera Advisors LLC
Allstate Corp  Shares Acquired by Cetera Advisors LLC
Allstate Corp Shares Acquired by Cetera Advisors LLC
14,315 Shares in Johnson & Johnson  Bought by Hummer Financial Advisory Services Inc
14,315 Shares in Johnson & Johnson Bought by Hummer Financial Advisory Services Inc
Cetera Advisors LLC Has $502,000 Holdings in Gilead Sciences, Inc.
Cetera Advisors LLC Has $502,000 Holdings in Gilead Sciences, Inc.


© 2006-2020 Ticker Report